Asian Scientist (Aug. 27, 2013) – The results from two Phase III clinical studies (GEMINI I and II) evaluating Takeda Pharmaceutical Company’s vedolizumab, an investigational monoclonal antibody drug for the treatment of ulcerative colitis and Crohn’s disease, have been published in the New England Journal of Medicine.
Ulcerative colitis and Crohn’s disease are two of the most common types of inflammatory bowel disease, which affects more than four million people worldwide.
The GEMINI I study showed that vedolizumab improved clinical response, achieving and maintaining clinical remission in patients with ulcerative colitis, while a separate study (GEMINI II) found that vedolizumab significantly improved clinical remission outcomes in patients with Crohn’s disease.
GEMINI I and GEMINI II are part of the four-study GEMINI Studies, studying vedolizumab in 2,700 patients in nearly 40 countries, making it the largest Phase 3 clinical trial program conducted to date simultaneously evaluating both Crohn’s disease and ulcerative colitis.
“These clinical studies suggest that vedolizumab may have the potential to maintain clinical remission in the appropriate patients,” said Dr Asit Parikh, vice president, general medicine, Takeda.
The articles can be found at:
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.